• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS=300175).
  

PubMed=994214; DOI=10.1093/jnci/56.6.1131
Giovanella B.C., Stehlin J.S. Jr., Santamaria C., Yim S.O., Morgan A.C. Jr., Williams L.J. Jr., Leibovitz A., Fialkow P.J., Mumford D.M.
Human neoplastic and normal cells in tissue culture. I. Cell lines derived from malignant melanomas and normal melanocytes.
J. Natl. Cancer Inst. 56:1131-1142(1976)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2624919; DOI=10.1007/BF01744892; PMCID=PMC11038635
Guarini L., Temponi M., Edwalds G.M., Vita J.R., Fisher P.B., Ferrone S.
In vitro differentiation and antigenic changes in human melanoma cell lines.
Cancer Immunol. Immunother. 30:262-268(1989)

PubMed=1898655; DOI=10.1172/JCI114984; PMCID=PMC295046
D'Urso C.M., Wang Z.-G., Cao Y., Tatake R.J., Zeff R.A., Ferrone S.
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.
J. Clin. Invest. 87:284-292(1991)

PubMed=8537970; DOI=10.1093/jnci/88.2.100; PMCID=PMC2248456
Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K., Yannelli J.R., Rosenberg S.A.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88:100-108(1996)

PubMed=15661905; DOI=10.4049/jimmunol.174.3.1462; PMCID=PMC2245899
Chang C.-C., Campoli M., Restifo N.P., Wang X.-H., Ferrone S.
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
J. Immunol. 174:1462-1471(2005)